Factors determining prevalence of maternal antibody to measles virus throughout infancy: A review

Clinical Infectious Diseases

Volumn 31, Issue 1, 2000, Pages 110-119

  Caceres V M ^a   Strebel, P M ^a   Sutter, R W ^a  

^a CENTERS FOR DIS CONTR AND PREV   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MATERNAL ANTIBODY;

ANTIBODY TITER; CHILD; DEVELOPING COUNTRY; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MEASLES; PLACENTAL TRANSFER; PREDICTION; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SEROCONVERSION; UMBILICAL CORD BLOOD; VACCINATION;

ANTIBODIES, VIRAL; FEMALE; HUMANS; IMMUNITY, MATERNALLY-ACQUIRED; INFANT, NEWBORN; MEASLES VIRUS; PREGNANCY; PREVALENCE;

EID: 0034457865     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/313926     Document Type: Review

References (75)

1. The modification of measles vaccination age as a consequence of the earlier decline of transplacentally transferred antimeasles antibodies in Turkish infants
2. Appropriate age for measles immunization in the United States
3. Progress toward elimination of measles from the Americas
4. Measles elimination in the Americas: Evolving strategies
5. Immunogenicity of high-titre AIKC or Edmonston-Zagreb vaccines in 3.5-month-old infants, and of medium or high-titre Edmonston-Zagreb vaccine in 6-month-old infants, in Kinshasa. Zaire
6. Global Advisory Group. II. Measles
7. Measles, mumps, and rubella vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps. Recommendations of the Advisory Committee on Immunization Practices (ACIP)
8. Loss of maternal measles antibody in black South African infants in the first year of life: Implications for age of vaccination
9. Measles immunity in children before one year of age: A pilot study
10. Persistence of maternal antibody in infants beyond 12 months: Mechanism of measles antibody failure
11. At what age should measles vaccine be given
12. Response to measles vaccine in Haitian infants 6 to 12 months old
13. The optimal age for vaccination against measles in an Asiatic city, Taipei, Taiwan: Reduction of vaccine induced titre by residual transplacental antibody
14. The optimal age for administering measles vaccine in developing countries
15. The effect of dose and strain of live attenuated measles vaccines on serological responses in young infants
16. Evolution of maternofetal transport of immunoglobulins during human pregnancy
17. Measles active and passive immunity in a worldwide perspective
18. Deficiency of the humoral immune response to measles vaccine in infants immunized at age 6 months
19. Reduced measles immunity in infants in a well-vaccinated population
20. Inadequate immunity to measles in children vaccinated at an early age: Effect of revaccination
21. The influence of maternally derived antibody on the efficacy of further attenuated measles vaccine
22. Immunization of six-month-old infants with different doses of Edmonston-Zagreb and Schwarz measles vaccines
23. Measles antibody: Reevaluation of protective titers
24. Enzyme-linked immunosorbent assay for evaluation of immunity to measles virus
25. Comparison of capillary blood versus venous blood samples in the assessment of immunity to measles
26. Geographic variation in infant loss of maternal measles antibody and in prevalence of rubella antibody
27. Transfer of measles immunoglobulins and antibodies from mother to child in Africa and Europe
28. Optimal age for vaccinating Zimbabwean children against measles
29. Durability of passive measles antibody in Jamaican children
30. A study of maternally derived measles antibody in infants born to naturally infected and vaccinated women
31. Maternal and cord blood measles antibody liters
32. Maternal immunity to measles and infant immunity at less than twelve months of age relative to maternal place of birth
33. Studies on immunity to measles
34. Maternally derived measles antibody in an era of vaccine protected mothers
35. Early loss of passive measles antibody in infants of mothers with vaccine-induced immunity
36. Measles antibodies in women and infants in the vaccine era
37. Changing levels of measles antibody titers in women and children in the United States: Impact on response to vaccination
38. The levels of measles antibodies in Nigerian children aged 0-12 months and its relationship with maternal parity
39. Maternal measles antibody decay in rural Bangladeshi infants: Implications for vaccination schedules
40. Measles in children under six months of age: An epidemiological study
41. Transfer of measles, mumps, and rubella antibodies from mother to infant
42. Optimum age of measles immunization: Maternal and transplacentally transmitted measles antibodies in infancy
43. Measles antibody tilers in early infancy
44. Passive immunity against measles during the first 8 months of life of infants born to vaccinated mothers who sustained measles
45. Placental transfer and maternally acquired neonatal IgG immunity in human immunodeficiency virus infection
46. Placental antibody transfer: Influence of maternal HIV infection and placental malaria
47. Loss of maternally acquired measles antibodies in well-nourished infants and response to measles vaccination, Peru
48. Measles immunity in the first year after birth and the optimum age for vaccination in Kenyan children
49. Measles antibody levels from birth to 9 months of age in Nigerian infants
50. Measles in Tanzania: Antibody response after vaccination and antibody state of mothers and newborns
51. Loss of maternal antibody in an African city
52. Loss of maternally-acquired measles antibody during infancy in Ilorin, Nigeria
53. Studies of measles in Thailand
54. Seroepidemiology of measles in Bombay
55. Age of measles immunization in tropics
56. Optimum age for measles immunization: Study of pre- and post-immunization level of Hi antibody titres
57. Disappearance of measles antibody in Thai infants after birth
58. Seroepidemiological study to determine age for measles vaccination
59. Seroepidemiology of measles in Delhi: Implication for age of vaccination
60. Measles antibody levels in 3 to 9 months old infants
61. Prevalence of placentally transmitted antibodies for measles in infants 3 to 11 months old in an urban slum community
62. Estudio de la persistencia de la inmunidad trasplacentaria antisarampion
63. Measles virus specific antibody in infants in a highly vaccinated society
64. Loss of maternally derived measles immunity in Argentinian infants
65. Study of measles neutralizing antibody levels in children in first months of life
66. Optimum age for measles immunization in Romania
67. Elimination of maternal antibodies against measles
68. Decay of maternally derived measles antibody in a highly vaccinated population in southern Israel
69. Maternally derived measles immunity in children of naturally infected and vaccinated mothers
70. Optimal age for vaccinating Nigerian children against measles. I. Neonatal antibody profile and subsequent susceptibility to measles
71. Separating the factors in measles vaccine failure
72. The problem of malaria and malaria control in pregnancy in sub-Saharan Africa
73. Measles in developing countries. I. Epidemiological parameters and patterns
74. Randimised trial of effect of vitamin A supplementation on antibody response to measles vaccine in Guinea-Bissau, West Africa